Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

[1]  Gabriel O Sawakuchi,et al.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. , 2016, International journal of radiation oncology, biology, physics.

[2]  T. Pawlik,et al.  Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. , 2016, International journal of radiation oncology, biology, physics.

[3]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[4]  R. Wolff,et al.  Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer , 2015, Acta oncologica.

[5]  P. Tran,et al.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma , 2015, American journal of clinical oncology.

[6]  S. Grossman,et al.  Association between severe treatment‐related lymphopenia and progression‐free survival in patients with newly diagnosed squamous cell head and neck cancer , 2014, Head & neck.

[7]  F. Rödel,et al.  Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. , 2014, Biochimica et biophysica acta.

[8]  D. Gomez,et al.  Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. , 2014, International journal of radiation oncology, biology, physics.

[9]  S. Demaria,et al.  The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation , 2014, Radiation research.

[10]  M. Lesina,et al.  The immune network in pancreatic cancer development and progression , 2014, Oncogene.

[11]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[12]  M. Brock,et al.  Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer , 2013, Cancer investigation.

[13]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[14]  S. Grossman,et al.  The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas , 2012, Cancer investigation.

[15]  K. Olive,et al.  Silencing the killers: paracrine immune suppression in pancreatic cancer. , 2012, Cancer Cell.

[16]  Steven D Chang,et al.  Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery. , 2012, International journal of radiation oncology, biology, physics.

[17]  Steve Webb,et al.  Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  H. Druid,et al.  The Desmoplastic Stroma Plays an Essential Role in the Accumulation and Modulation of Infiltrated Immune Cells in Pancreatic Adenocarcinoma , 2011, Clinical & developmental immunology.

[19]  S. Piantadosi,et al.  Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.

[20]  J. Plate.  Clinical trials of vaccines for immunotherapy in pancreatic cancer , 2011, Expert review of vaccines.

[21]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[22]  H. Nagawa,et al.  Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer , 2011, BMC Cancer.

[23]  L. Zitvogel,et al.  Chemotherapy and radiotherapy: cryptic anticancer vaccines. , 2010, Seminars in immunology.

[24]  S. Demaria,et al.  Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation , 2010, Radiation research.

[25]  S. Demaria,et al.  Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.

[26]  R. Schreiber,et al.  Immune‐mediated dormancy: an equilibrium with cancer , 2008, Journal of leukocyte biology.

[27]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[28]  V A Semenenko,et al.  Lyman–Kutcher–Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data , 2008, Physics in medicine and biology.

[29]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[30]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[31]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[32]  V. Reuter,et al.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.

[33]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[34]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[35]  H. Kitagawa,et al.  Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. , 2001, International journal of oncology.

[36]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[37]  G Bellone,et al.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.

[38]  R. Day,et al.  Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. , 1998, Cancer research.

[39]  C. Burman,et al.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. , 1989, International journal of radiation oncology, biology, physics.

[40]  N. Di Lorenzo,et al.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. , 1978, Journal of neurosurgery.

[41]  K. Meyer.  Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. , 1970, Archives of surgery.

[42]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[43]  H. Kitagawa,et al.  Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. , 2001, International journal of oncology.

[44]  J. Lyman.  Complication Probability as Assessed from Dose-Volume Histograms , 1985 .

[45]  D. Cox.  Regression Models and Life-Tables , 1972 .